Alemtuzumab News and Research

RSS
Scientists discover adverse, unpredictable side effects of approved MS therapy

Scientists discover adverse, unpredictable side effects of approved MS therapy

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Promising results for stem cell therapy in MS

Promising results for stem cell therapy in MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

ANMAT approves Genzyme’s Lemtrada for treatment of relapsing remitting multiple sclerosis

Genzyme: FDA accepts resubmission of Lemtrada sBLA

Genzyme: FDA accepts resubmission of Lemtrada sBLA

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

New study reveals way to combat drug-resistant tumors

New study reveals way to combat drug-resistant tumors

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Viewpoints: Is overhaul really a 'war' on the young?; war on poverty requires spending; maternity leave in America

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Genzyme gets FDA Complete Response Letter for Lemtrada sBLA

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

EMA's CHMP issues positive opinion for approval of Genzyme's LEMTRADA in Europe

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

Genmab, ADC Therapeutics agree to develop new antibody-drug conjugate product

FDA accepts Genzyme’s LEMTRADA sBLA for review

FDA accepts Genzyme’s LEMTRADA sBLA for review

Lymphocyte clue to multiple sclerosis drug response

Lymphocyte clue to multiple sclerosis drug response

Doctors should use different therapies when treating older and younger patients with CLL

Doctors should use different therapies when treating older and younger patients with CLL